Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) predominantly affect elderly patients with significant comorbidities.
• Current treatment options for relapsed/refractory CLL/SLL have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of idelalisib, a selective PI3Kδ inhibitor, in patients with relapsed CLL and SLL.
• To assess idelalisib's mechanism of action, including its effects on CLL cell apoptosis and microenvironmental interactions.

Main Methods:

• Idelalisib was administered as monotherapy and in combination therapy.
• Ex vivo studies assessed idelalisib's impact on primary CLL cell apoptosis.
• Inhibition of CLL cell homing, migration, and adhesion to the microenvironment was evaluated.

Main Results:

• Idelalisib demonstrated efficacy as both monotherapy and combination therapy in relapsed/refractory CLL.
• The drug promotes apoptosis in primary CLL cells independently of prognostic markers.
• Idelalisib inhibits CLL cell homing, migration, and adhesion within the tumor microenvironment.
• Clinical activity was observed in patients with CLL harboring the del(17p) genetic abnormality.

Conclusions:

• Idelalisib is an effective first-in-class PI3Kδ inhibitor for treating relapsed CLL and SLL, including in elderly patients with comorbidities.
• Idelalisib's mechanism involves promoting apoptosis and disrupting CLL cell interactions within the microenvironment.
• Further investigation into idelalisib combinations with novel B-cell-targeted agents may enhance treatment outcomes for CLL/SLL.